{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:42:56Z","timestamp":1791330176650,"version":"4.3.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11892-019-1178-6","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T04:03:56Z","timestamp":1563768236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition"],"prefix":"10.1007","volume":"19","author":[{"given":"Paul D.","family":"Rosenblit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association. Circulation. 2019;139:e1\u2013e473. https:\/\/doi.org\/10.1161\/CIR.0000000000000659 .","journal-title":"Circulation."},{"key":"1178_CR2","unstructured":"National vital statistics reports, vol 50, No. 6. Life expectancy at birth, by race and sex, selected years 1929\u201398."},{"issue":"3","key":"1178_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2105\/AJPH.41.3.279","volume":"41","author":"TR Dawber","year":"1951","unstructured":"Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279\u201381.","journal-title":"Am J Public Health Nations Health"},{"key":"1178_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","volume":"55","author":"WB Kannel","year":"1961","unstructured":"Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease: six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33\u201350.","journal-title":"Ann Intern Med"},{"issue":"8B","key":"1178_CR5","first-page":"B53","volume":"34","author":"WB Kannel","year":"1988","unstructured":"Kannel WB. Cholesterol and risk of coronary heart disease and mortality in men. Clin Chem. 1988;34(8B):B53\u20139.","journal-title":"Clin Chem"},{"key":"1178_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707\u201314.","journal-title":"Am J Med"},{"key":"1178_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0002-8703(87)90964-1","volume":"114","author":"WB Kannel","year":"1987","unstructured":"Kannel WB. New perspectives on cardiovascular risk factors. Am Heart J. 1987;114:213\u20139.","journal-title":"Am Heart J"},{"issue":"7455","key":"1178_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","volume":"328","author":"R Doll","year":"2004","unstructured":"Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50\u00a0years\u2019 observations on male British doctors. BMJ. 2004;328(7455):1519. https:\/\/doi.org\/10.1136\/bmj.38142.554479.AE .","journal-title":"BMJ"},{"key":"1178_CR9","first-page":"CD003041","volume":"4","author":"J Critchley","year":"2003","unstructured":"Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2003;4:CD003041.","journal-title":"Cochrane Database Syst Rev"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/0021-9681(67)90082-3","volume":"20","author":"J Truett","year":"1967","unstructured":"Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis. 1967;20:511\u201324.","journal-title":"J Chronic Dis"},{"issue":"1","key":"1178_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","volume":"83","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Wilson PWF, Odell PM, Kannel WB. AHA Medica1IScientific statement science advisory an updated coronary risk profile a statement for health professionals. Circulation. 1991;83(1):356\u201362.","journal-title":"Circulation."},{"key":"1178_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837\u201347.","journal-title":"Circulation."},{"issue":"9147","key":"1178_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(98)10279-9","volume":"353","author":"DM Lloyd-Jones","year":"1999","unstructured":"Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(98)10279-9 .","journal-title":"Lancet"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1157\/13116658","volume":"61","author":"CJ O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell CJ, Elosua R. Cardiovascular risk factors. Insights from Framingham Heart Study. Rev. Esp Cardiol. 2008;61:299\u2013310.","journal-title":"Rev. Esp Cardiol"},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/0735-1097(90)90203-2","volume":"15","author":"WB Kannel","year":"1990","unstructured":"Kannel WB. Contribution of the Framingham Study to preventive cardiology. JACC. 1990;15:206\u201311.","journal-title":"JACC."},{"issue":"25","key":"1178_CR16","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB Sr, Gibbons R, et al. 2013 ACC\/AHA Guideline on the Assessment of cardiovascular risk. a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Am Coll Cardiol. 2014;63(25):2935\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.005 .","journal-title":"Am Coll Cardiol"},{"issue":"1","key":"1178_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","volume":"148","author":"DeWitt S. Goodman","year":"1988","unstructured":"Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, LaRosa JC, et al. Report of the National Cholesterol Treatment of High Blood Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148(1):36\u201369.","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"1178_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/01.CIR.89.3.1333","volume":"89","author":"SM Grundy","year":"1994","unstructured":"Grundy SM, Bilheimer D, Chait A, Clark LT, Denke M, Havel RJ, et al. Adult treatment Panel II. National Cholesterol Education Program. Second Report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 1994;89(3):1333\u2013435.","journal-title":"Circulation."},{"key":"1178_CR19","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u201321.","journal-title":"Circulation"},{"key":"1178_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0002-8703(93)90182-9","volume":"125","author":"LA Cupples","year":"1993","unstructured":"Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993;125:863\u201372.","journal-title":"Am Heart J"},{"issue":"4","key":"1178_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00043798-199412000-00009","volume":"1","author":"WB Kannel","year":"1994","unstructured":"Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk. 1994;1(4):333\u20139.","journal-title":"J Cardiovasc Risk"},{"issue":"6","key":"1178_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1056\/NEJM199202063260605","volume":"326","author":"MH Criqui","year":"1992","unstructured":"Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10\u00a0years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381\u20136.","journal-title":"N Engl J Med"},{"issue":"8","key":"1178_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archneur.1992.00530320089016","volume":"49","author":"JI Wilterdink","year":"1992","unstructured":"Wilterdink JI, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol. 1992;49(8):857\u201363.","journal-title":"Arch Neurol"},{"issue":"22","key":"1178_CR24","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"SC Smith Jr","year":"2011","unstructured":"Smith SC Jr, Benjamin EJ, Bonow R, Braun LT, Creager MA, Franklin BA, et al. AHA\/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458\u201373. https:\/\/doi.org\/10.1161\/CIR.0b013e318235eb4d .","journal-title":"Circulation"},{"key":"1178_CR25","doi-asserted-by":"publisher","unstructured":"Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811\u201322. https:\/\/doi.org\/10.2337\/dc08-9018 . and J Am Coll Cardiol 2008;51:1513\u20131524. https:\/\/doi.org\/10.1016\/j.jacc.2008.02.034 .","DOI":"10.2337\/dc08-9018 10.1016\/j.jacc.2008.02.034"},{"issue":"Suppl 1","key":"1178_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.18.S1.1","volume":"18","author":"PS Jellinger","year":"2012","unstructured":"Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists\u2019 guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1\u201378. https:\/\/doi.org\/10.4158\/EP.18.S1.1 .","journal-title":"Endocr Pract"},{"key":"1178_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 \u2013 full report. J Clin Lipidol. 2015;9:129\u201369. https:\/\/doi.org\/10.1016\/j.jacl.2015.02.003 .","journal-title":"J Clin Lipidol."},{"issue":"39","key":"1178_CR28","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/eas guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272 .","journal-title":"Eur Heart J"},{"key":"1178_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med. 1998;339:229\u201334.","journal-title":"N Eng J Med"},{"key":"1178_CR30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/01.CIR.102.9.1014","volume":"102","author":"K Malmberg","year":"2000","unstructured":"Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014\u20139.","journal-title":"Circulation."},{"issue":"2","key":"1178_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/archinte.161.2.242","volume":"161","author":"PA Lotufo","year":"2001","unstructured":"Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Mereno-John G, Buring JE, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161(2):242\u20137.","journal-title":"Arch Intern Med"},{"key":"1178_CR32","doi-asserted-by":"publisher","unstructured":"Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. for the GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes: the global registry of acute coronary events. Arch Intern Med. 2004;164:1457\u201363. https:\/\/doi.org\/10.1001\/archinte.164.13.1457 .","DOI":"10.1001\/archinte.164.13.1457"},{"issue":"12","key":"1178_CR33","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2337\/diacare.28.12.2901","volume":"28","author":"A. Juutilainen","year":"2005","unstructured":"Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laasko M. Type 2 diabetes as a \u201ccoronary heart disease equivalent\u201d: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901\u20137. https:\/\/doi.org\/10.2337\/diacare.28.12.2901 .","journal-title":"Diabetes Care"},{"key":"1178_CR34","doi-asserted-by":"publisher","unstructured":"Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G. Stamler J; Multiple Risk Factor Intervention Trial Research Group. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med. 2004;164(13):1438\u201343. https:\/\/doi.org\/10.1001\/archinte.164.13.1438 .","DOI":"10.1001\/archinte.164.13.1438"},{"key":"1178_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/diacare.28.7.1588","volume":"28","author":"L Whiteley","year":"2005","unstructured":"Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent?: Results from 25\u00a0years of follow-up in the Renfrew and Paisley survey. Diabetes Care. 2005;28:1588\u201393.","journal-title":"Diabetes Care"},{"key":"1178_CR36","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","volume":"117","author":"TK Schramm","year":"2008","unstructured":"Schramm TK, Gislason GH, K\u00f8ber L, Rasmussen S, Rasmussen JN, Abildstr\u00f8m SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.720847 .","journal-title":"Circulation."},{"issue":"12","key":"1178_CR37","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"Deepak L. Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. for the REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350\u20137. https:\/\/doi.org\/10.1001\/jama.2010.1322 .","journal-title":"JAMA"},{"key":"1178_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ahj.2010.10.019","volume":"161","author":"D Preiss","year":"2011","unstructured":"Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J. 2011;161:210\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2010.10.019 .","journal-title":"Am Heart J"},{"issue":"2","key":"1178_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/diacare.29.02.06.dc05-1904","volume":"29","author":"SM Grundy","year":"2006","unstructured":"Grundy SM. Diabetes and coronary risk equivalency. What does it mean? Diabetes Care. 2006;29(2):457\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"1178_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","volume":"26","author":"U Bulugahapitiya","year":"2009","unstructured":"Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02640.x .","journal-title":"Diabet Med"},{"key":"1178_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2013.05.003","volume":"9","author":"CH Saely","year":"2013","unstructured":"Saely CH, Drexel H. Is type 2 diabetes really a coronary heart disease risk equivalent? Vasc Pharmacol. 2013;9:11\u20138. https:\/\/doi.org\/10.1016\/j.vph.2013.05.003 .","journal-title":"Vasc Pharmacol"},{"issue":"2","key":"1178_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2337\/diacare.29.02.06.dc05-1299","volume":"29","author":"B. V. Howard","year":"2006","unstructured":"Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29(2):391\u20137. https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1299 .","journal-title":"Diabetes Care"},{"issue":"10","key":"1178_CR43","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","volume":"110","author":"Shaista Malik","year":"2004","unstructured":"Malik S, Wong ND, Franklin SS, Kamath TV, L\u2019Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245\u201350. https:\/\/doi.org\/10.1161\/01.CIR.0000140677.20606.0E .","journal-title":"Circulation"},{"issue":"Supplement 2","key":"1178_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"\u2022\u2022 Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. 2017 AACE\/ACE Guidelines American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Supplement 2):1\u201387. https:\/\/doi.org\/10.4158\/EP171764.APPGL . The 2017 AACE\/ACE dyslipidemia guideline introduced the concept of partitioning the very high\u2013ASCVD risk category in recognition of the more ominous multi-morbidities described by the \u201cextreme\u201d\u2013risk category and with targeted atherogenic cholesterol markers (LDL-C, non-HDL-C, and Apo B goals <\u200955\u00a0mg\/dL, <\u200980\u00a0mg\/dL, and\u2009<\u200970\u00a0mg\/dL, respectively) based on the IMPROVE-IT trial that demonstrated additional benefits beyond guidelines at that time.","journal-title":"Endocr Pract"},{"issue":"1","key":"1178_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"\u2022\u2022 Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52\u201360. https:\/\/doi.org\/10.1001\/jama.2015.7008 . This a very large epidemiological study describing the differences in years-of-life-lost among patients with a single morbidity (diabetes, MI, or stroke) versus patients with multi-morbidities, relative to individuals without a history of diabetes, stroke, or MI.","journal-title":"JAMA"},{"key":"1178_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227\u201339. https:\/\/doi.org\/10.1161\/01.CIR.0000133317.49796.0E .","journal-title":"Circulation"},{"key":"1178_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","volume":"113","author":"DM Lloyd-Jones","year":"2006","unstructured":"Lloyd-Jones DM, Leip EP, Larson MG, D\u2019Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50\u00a0years of age. Circulation. 2006;113:791\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.548206 .","journal-title":"Circulation."},{"issue":"4","key":"1178_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1012848","volume":"366","author":"JD Berry","year":"2012","unstructured":"Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1012848 .","journal-title":"N Engl J Med"},{"key":"1178_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ahj.2016.09.002","volume":"184","author":"JD Newman","year":"2017","unstructured":"Newman JD, Rockman CB, Kosiborod M, Guo Y, Zhong H, Weintraub HS, et al. Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. Am Heart J. 2017;184:114\u201320. https:\/\/doi.org\/10.1016\/j.ahj.2016.09.002 .","journal-title":"Am Heart J"},{"key":"1178_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/1471-2458-10-338","volume":"10","author":"S Brophy","year":"2010","unstructured":"Brophy S, Cooksey R, Gravenor MB, Weston C, Macey SM, John G, et al. Population based absolute and relative survival to 1\u00a0year of people with diabetes following a myocardial infarction: a cohort study using hospital admissions data. Brophy et al. BMC Public Health. 2010;10:338 http:\/\/www.biomedcentral.com\/1471-2458\/10\/338 .","journal-title":"BMC Public Health"},{"key":"1178_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jech-2016-207402","volume":"71","author":"OA Alabas","year":"2017","unstructured":"Alabas OA, Hall H, Dondo TB, Rutherford MJ, Timmis AD, Batin PD, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study. J Epidemiol Community Health. 2017;71:25\u201332. https:\/\/doi.org\/10.1136\/jech-2016-207402 .","journal-title":"J Epidemiol Community Health"},{"issue":"9529","key":"1178_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","volume":"368","author":"GL Booth","year":"2006","unstructured":"Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(06)68967-8 .","journal-title":"Lancet"},{"issue":"6","key":"1178_CR53","doi-asserted-by":"publisher","first-page":"556.e1","DOI":"10.1016\/j.amjmed.2009.11.023","volume":"123","author":"MR Carnethon","year":"2010","unstructured":"Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123(6):556.e1\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2009.11.023 .","journal-title":"Am J Med"},{"issue":"2","key":"1178_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4158\/EP161682.CS","volume":"23","author":"AJ Garber","year":"2017","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2017 Executive Summary. Endocr Pract. 2017;23(2):207\u201338. https:\/\/doi.org\/10.4158\/EP161682.CS .","journal-title":"Endocr Pract"},{"issue":"25","key":"1178_CR55","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489 .","journal-title":"N Engl J Med"},{"key":"1178_CR56","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.amjcard.2006.07.036","volume":"98","author":"WC Cromwell","year":"2006","unstructured":"Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100\u00a0mg\/dl. Am J Cardiol. 2006;98:1599\u2013602. https:\/\/doi.org\/10.1016\/j.amjcard.2006.07.036 .","journal-title":"Am J Cardiol"},{"key":"1178_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306249 .","journal-title":"Circ Res"},{"key":"1178_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337\u201345. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.959247 .","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1178_CR59","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","volume":"53","author":"JG Robinson","year":"2009","unstructured":"Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.024 .","journal-title":"J Am Coll Cardiol"},{"key":"1178_CR60","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/archinte.164.13.1457","volume":"164","author":"K Franklin","year":"2004","unstructured":"Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. for the GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch. Intern Med. 2004;164:1457\u201363. https:\/\/doi.org\/10.1001\/archinte.164.13.1457 .","journal-title":"Intern Med"},{"issue":"7578","key":"1178_CR61","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","volume":"333","author":"KA Fox","year":"2006","unstructured":"Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. https:\/\/doi.org\/10.1136\/bmj.38985.646481.55 .","journal-title":"BMJ"},{"key":"1178_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2007.02.046","volume":"100","author":"D Mukherjee","year":"2007","unstructured":"Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100:1\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2007.02.046 .","journal-title":"Am J Cardiol"},{"issue":"15","key":"1178_CR63","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/NEJMoa040583 .","journal-title":"N Engl J Med"},{"issue":"25","key":"1178_CR64","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","volume":"54","author":"SA Murphy","year":"2009","unstructured":"Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes. JACC. 2009;54(25):2358\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.005 .","journal-title":"JACC."},{"key":"1178_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","volume":"67","author":"SA Murphy","year":"2016","unstructured":"Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al. Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.077 .","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1178_CR66","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174 .","journal-title":"N Engl J Med"},{"issue":"10","key":"1178_CR67","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","volume":"134","author":"D Nanchen","year":"2016","unstructured":"Nanchen D, Gencer B, Muller O, Auer R, Aghlmandi S, Heg D, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134(10):698\u2013709. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023007 .","journal-title":"Circulation."},{"key":"1178_CR68","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/CIRCINTERVENTIONS.108.847459.108.847459","volume":"2","author":"JS Berger","year":"2009","unstructured":"Berger JS, Petersen JL, Brown DL. Vascular disease burden and in-hospital outcomes among patients undergoing percutaneous coronary intervention in New York State. Circ Cardiovasc Interv. 2009;2:317\u201322. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.108.847459.108.847459 .","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"1178_CR69","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1185\/03007990903223895","volume":"25","author":"S Yakubov","year":"2009","unstructured":"Yakubov S. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Curr Med Res Opin. 2009;25(11):2631\u201341. https:\/\/doi.org\/10.1185\/03007990903223895 .","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"1178_CR70","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664 .","journal-title":"N Engl J Med"},{"issue":"4","key":"1178_CR71","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338\u201350 and supplemental material. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032235 .","journal-title":"Circulation"},{"issue":"6","key":"1178_CR72","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1172\/JCI110941","volume":"71","author":"I Ringqvist","year":"1983","unstructured":"Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, et al. Prognostic value of angiographic indices of coronary artery disease from the coronary artery surgery study (CASS). J Clin Invest. 1983;71(6):1854\u201366.","journal-title":"J Clin Invest"},{"issue":"1","key":"1178_CR73","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1440-1797.2009.01150.x","volume":"15","author":"F Sun","year":"2010","unstructured":"Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among 118,924 non-diabetic Taiwanese in a retrospective cohort. Nephrology (Carlton). 2010;15(1):84\u201392. https:\/\/doi.org\/10.1111\/j.1440-1797.2009.01150.x .","journal-title":"Nephrology (Carlton)"},{"issue":"9784","key":"1178_CR74","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(11)60739-3 .","journal-title":"Lancet"},{"key":"1178_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12170-010-0088-6","volume":"4","author":"P Muntner","year":"2010","unstructured":"Muntner P, Farkouh ME. Chronic kidney disease as a coronary heart disease risk equivalent. Curr Cardiovasc Risk Rep. 2010;4:136\u201341. https:\/\/doi.org\/10.1007\/s12170-010-0088-6 .","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"3","key":"1178_CR76","doi-asserted-by":"publisher","first-page":"340,1","DOI":"10.1007\/s11886-012-0340-4","volume":"15","author":"A Briasoulis","year":"2013","unstructured":"Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr. Cardiol. Rep. 2013;15(3):340,1\u20136. https:\/\/doi.org\/10.1007\/s11886-012-0340-4 .","journal-title":"Rep."},{"key":"1178_CR77","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238\u201348. https:\/\/doi.org\/10.1056\/NEJMoa043545 .","journal-title":"N Engl J Med"},{"issue":"14","key":"1178_CR78","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa0810177 .","journal-title":"N Engl J Med"},{"issue":"9645","key":"1178_CR79","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(08)61240-4 .","journal-title":"Lancet"},{"key":"1178_CR80","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, B\u00f6hm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248\u201361. https:\/\/doi.org\/10.1056\/NEJMoa0706201 .","journal-title":"N Engl J Med"},{"key":"1178_CR81","doi-asserted-by":"publisher","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281\u2013344. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.018 . and Eur Heart J. 2016;37(39):2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","DOI":"10.1016\/j.atherosclerosis.2016.08.018 10.1093\/eurheartj\/ehw272"},{"issue":"5","key":"1178_CR82","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","volume":"5","author":"MH Davidson","year":"2011","unstructured":"Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338\u201367. https:\/\/doi.org\/10.1016\/j.jacl.2011.07.005 .","journal-title":"J Clin Lipidol."},{"issue":"1","key":"1178_CR83","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","volume":"8","author":"SM Grundy","year":"2014","unstructured":"Grundy SM, Arai H, Barter P, Bersot TP, Betteridge DJ, Carmena R, et al. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. J Clin Lipidol. 2014;8(1):29\u201360. https:\/\/doi.org\/10.1016\/j.jacl.2013.12.005 .","journal-title":"J Clin Lipidol"},{"issue":"25","key":"1178_CR84","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"Neil J. Stone","year":"2014","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;24;129;25(Suppl 2): S1\u201345 and J Am Coll Cardiol. 2014;63:2889\u20132934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002","journal-title":"Journal of the American College of Cardiology"},{"key":"1178_CR85","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacl.2014.08.004","volume":"8","author":"PP Toth","year":"2014","unstructured":"Toth PP, Thanassoulis G, Williams K, Furberg CD, Sniderman A. The risk-benefit paradigm vs the causal exposure paradigm: LDL as a primary cause of vascular disease. J Clin Lipidol. 2014;8:594\u2013605. https:\/\/doi.org\/10.1016\/j.jacl.2014.08.004 .","journal-title":"J Clin Lipidol"},{"issue":"S1","key":"1178_CR86","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.3909\/ricm19S1S0004","volume":"19","author":"JG Robinson","year":"2018","unstructured":"Robinson JG, Watson KE. Identifying patients for nonstatin therapy. Rev Cardiovasc Med. 2018;19(S1):S1\u20138.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"1178_CR87","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"DM Lloyd-Jones","year":"2016","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.519 .","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"1178_CR88","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.2337\/dc16-S011","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In Standards of Medical Care in Diabetes 2016. Diabetes Care. 2016;39(Suppl. 1):S60\u201371. https:\/\/doi.org\/10.2337\/dc16-S011 .","journal-title":"Diabetes Care"},{"issue":"4","key":"1178_CR89","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","volume":"52","author":"SJ Nicholls","year":"2008","unstructured":"Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon K-W, Sipahi I, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling. A pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2008.03.051 .","journal-title":"J Am Coll Cardiol"},{"key":"1178_CR90","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.2337\/dc14-1121","volume":"37","author":"B Stegman","year":"2014","unstructured":"Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, et al. High intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: Insights from SATURN. Diabetes Care. 2014;37:3114\u201320, and Supplement. https:\/\/doi.org\/10.2337\/dc14-1121 .","journal-title":"Diabetes Care"},{"issue":"32","key":"1178_CR91","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. for the European Atherosclerosis Society Consensus Panel on familial homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274 .","journal-title":"Eur Heart J"},{"issue":"2","key":"1178_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/01.CIR.79.2.225","volume":"79","author":"H Mabuchi","year":"1989","unstructured":"Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 1989;79(2):225\u201332.","journal-title":"Circulation."},{"key":"1178_CR93","first-page":"2863","volume-title":"The metabolic and molecular bases of inherited disease","author":"JL Goldstein","year":"2001","unstructured":"Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Companies, Inc.; 2001. p. 2863\u2013914."},{"issue":"5","key":"1178_CR94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/aje\/kwh237","volume":"160","author":"MA Austin","year":"2004","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: A HuGE Association Review. Am J Epidemiol. 2004;160(5):421\u20139. https:\/\/doi.org\/10.1093\/aje\/kwh237 .","journal-title":"Am J Epidemiol"},{"issue":"22","key":"1178_CR95","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.520 .","journal-title":"J Am Coll Cardiol"},{"issue":"9965","key":"1178_CR96","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340.","journal-title":"Lancet."},{"issue":"4","key":"1178_CR97","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ehjqcco\/qcx011","volume":"3","author":"G Villa","year":"2017","unstructured":"Villa G, Wong B, Kutikova L, Ray KK, Mata P, Bruckert E. Prediction of cardiovascular risk in patients with familial hypercholesterolemia. Eur Heart J Qual Care Clin Outcomes. 2017;3(4):274\u201380. https:\/\/doi.org\/10.1093\/ehjqcco\/qcx011 .","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1178_CR98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jacc.2010.09.001","volume":"56","author":"P Greenland","year":"2010","unstructured":"Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation\/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:50\u2013103. https:\/\/doi.org\/10.1016\/j.jacc.2010.09.001 .","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1178_CR99","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jacc.2003.09.068","volume":"43","author":"P Raggi","year":"2004","unstructured":"Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43(9):1663\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2003.09.068 .","journal-title":"J Am Coll Cardiol"},{"issue":"2A","key":"1178_CR100","doi-asserted-by":"publisher","first-page":"2H","DOI":"10.1016\/j.amjcard.2006.03.002","volume":"98","author":"M Naghavi","year":"2006","unstructured":"Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient--Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98(2A):2H\u201315H. https:\/\/doi.org\/10.1016\/j.amjcard.2006.03.002 .","journal-title":"Am J Cardiol"},{"issue":"5","key":"1178_CR101","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jcmg.2015.02.006","volume":"8","author":"HS Hecht","year":"2015","unstructured":"Hecht HS. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging. 2015;8(5):579\u201396. https:\/\/doi.org\/10.1016\/j.jcmg.2015.02.006 .","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"1178_CR102","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3 .","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"1178_CR103","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.745 .","journal-title":"J Am Coll Cardiol"},{"key":"1178_CR104","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;Nov 10. online. https:\/\/doi.org\/10.1161\/CIR.0000000000000625 and J Am Coll Cardiol. 2018. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003 .","DOI":"10.1161\/CIR.0000000000000625 10.1016\/j.jacc.2018.11.003"}],"updated-by":[{"DOI":"10.1007\/s11892-019-1257-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000}}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1178-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-019-1178-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1178-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T05:37:16Z","timestamp":1663997836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-019-1178-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1178-6","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"22 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"<b>12-month 1\/1\/18-12\/31\/18 disclosure<\/b>Paul D. Rosenblit received clinical trial research site funding from Amgen, AstraZeneca, Dexcom, GlaxoSmithKline, Ionis, Mylan, and Novo Nordisk. He received speaker faculty honoraria from Akcea, Amgen, Merck, and Novo Nordisk. He received advisory board honoraria from Akcea, Esperion, and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"61"}}